Displaying drugs 7226 - 7250 of 8282 in total
Sovleplenib
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).
Investigational
Matched Description: … It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly …
SRP-9005
SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.
Investigational
Matched Description: … Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of …
Piclamilast
Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent...
Experimental
Matched Description: … It has been investigated for its applications to the treatment of conditions such as chronic obstructive ... first elucidated in a 1995 European patent application and exhibits the structural functionalities of …
Rindopepimut
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted...
Investigational
Matched Description: … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated ... injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of …
Velafermin
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple animal models. Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the...
Investigational
Matched Description: … by fostering the regeneration and repair of the cells lining the gastrointestinal tract. ... Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis …
Valopicitabine
The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus (HCV) activity. Upon administration, valopicitabine is converted into 2'-C-methylcytidine; upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity. This blocks viral production of HCV RNA and thus...
Experimental
Matched Description: … This blocks viral production of HCV RNA and thus viral replication. [from NCI] ... The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus …
Erythroxylum catuaba bark
"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the Erythroxylum genus, though this name is also applied to infusions of plants belonging to other genera. The infusion is thought to carry stimulant and aphrodisiac effects, and catuaba made specifically with Trichilia...
Experimental
Matched Description: … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _ ... Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera …
CVnCoV Vaccine
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … Phase 1 clinical trials of this vaccine (NCT04449276). ... As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
XL999
XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and...
Investigational
Matched Description: … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth ... growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of …
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
Matched Description: … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct ... On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its …
AV-COVID-19
AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).
The vaccine is created from the receiving patients’ isolated peripheral blood monocytes. The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2...
Investigational
Matched Description: … AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with ... As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252 …
MVA3000
MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or skin conditions such as eczema.
Investigational
Matched Description: … people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of …
IDM-2
IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Investigational
Matched Description: … IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. …
Ciliary neurotrophic factor
NT-501 is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). It is under investigation for the treatment of retinitis pigmentosa and age-related macular degeneration.
Investigational
Matched Description: … [L46762] It is under investigation for the treatment of retinitis pigmentosa and age-related macular …
Reparixin
Reparixin has been used in trials studying the treatment and prevention of Breast Cancer, Metastatic Breast Cancer, Pancreatectomy for Chronic Pancreatitis, Islet Transplantation in Diabetes Mellitus Type 1, and Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus.
Investigational
Matched Description: … Reparixin has been used in trials studying the treatment and prevention of Breast Cancer, Metastatic …
Inolimomab
Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.
Investigational
Matched Description: … far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of …
Nurulimab
Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in Subjects With Unresectable/metastatic Melanoma).
Investigational
Matched Description: … Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab …
Dihydroxyacetone
A ketotriose compound. Its addition to blood preservation solutions results in better maintenance of 2,3-diphosphoglycerate levels during storage. It is readily phosphorylated to dihydroxyacetone phosphate by triokinase in erythrocytes. In combination with naphthoquinones it acts as a sunscreening agent. [PubChem]
Experimental
Matched Description: … Its addition to blood preservation solutions results in better maintenance of 2,3-diphosphoglycerate …
105AD7
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
Matched Description: … responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of …
AME-527
AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.
Investigational
Matched Description: … AME-527 was generated by protein engineering and identified from a library of antibody variants based …
Autologous Non-Hematopoietic Peripheral Blood Stem Cells
Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center. The cells have the characterizations of CD90+, CD133+, Oct-4+, CD45-, and CD71-.
Investigational
Matched Description: … The cells have the characterizations of CD90+, CD133+, Oct-4+, CD45-, and CD71-.[L16363] …
Vibostolimab
Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)).
Investigational
Matched Description: … Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of …
RH-1
RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma.
Experimental
Investigational
Matched Description: … RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma …
GlycoPEG-GCSF
GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
Investigational
Matched Description: … GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of …
TAK-751S
TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic Escherichia coli.
Investigational
Matched Description: … TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia …
Displaying drugs 7226 - 7250 of 8282 in total